News
ABCL
3.260
+5.16%
0.160
Weekly Report: what happened at ABCL last week (0715-0719)?
Weekly Report · 4d ago
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. Julian and Felix Baker made bets on more than a dozen stocks in the first three months of 2024. Shares of AbCellera Biologics and Fate Therapeutics are down more than 40% from their peaks.
The Motley Fool · 5d ago
Weekly Report: what happened at ABCL last week (0708-0712)?
Weekly Report · 07/15 09:13
Possible Turnaround For AbCellera Biologics Insiders, Still Down US$203k
Insiders bought US$516.4k worth of AbCellera Biologics Inc. Stock in the last year. The company's share price has risen 15% since the purchase of US$5.90 per share. In the last 12 months Abcellera Biologistics insiders were buying shares at a higher price. It holds 27% of the company. The price of a company's shares is important to consider. AbCellERA Biologic insiders own about 27% of Ab cellera Biologicics.
Simply Wall St · 07/12 13:10
AbCellera Biologics Is Maintained at Overweight by Keybanc
Dow Jones · 07/11 11:30
AI Could Revolutionize Drug Discovery: A Look at Key Players 
TipRanks · 07/08 14:53
Weekly Report: what happened at ABCL last week (0701-0705)?
Weekly Report · 07/08 09:13
Weekly Report: what happened at ABCL last week (0624-0628)?
Weekly Report · 07/01 09:13
TD Cowen Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
TipRanks · 06/28 11:58
Press Release: AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
Dow Jones · 06/25 20:29
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
AbCellera will announce its second quarter 2024 financial results on August 6, 2024. The company will hold an earnings conference call the same day. AbCellera discovers and develops antibody medicines for indications including cancer, metabolic and endocrine conditions, and autoimmune disorders. Abcellera will release its second quarterly 2024 financial Results.
Barchart · 06/25 15:05
Weekly Report: what happened at ABCL last week (0617-0621)?
Weekly Report · 06/24 09:14
Weekly Report: what happened at ABCL last week (0610-0614)?
Weekly Report · 06/17 09:13
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Wall Street analysts say AbCellera Biologics can more than double your money. Shares of this biotech stock are down 57% from their high last summer. The company has 13 partnered antibodies in clinical-stage testing. The FDA rescinded authorization of the antibodies it licensed to Eli Lilly in 2022.
The Motley Fool · 06/13 09:40
Tracking Baker Brothers Portfolio - Q1 2024 Update
Seeking Alpha · 06/11 04:24
Weekly Report: what happened at ABCL last week (0603-0607)?
Weekly Report · 06/10 09:13
Weekly Report: what happened at ABCL last week (0527-0531)?
Weekly Report · 06/03 09:14
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
AbCellera Biologics's operating revenue has fallen 80% in the last year. The company burnt through US$128m in the past year to fund its growth. Its cash burn is a measure of the amount of cash the company is spending to fund growth. Ab cellera biologics has zero debt and has a cash runway of about 10 years. We think its falling revenue is a warning sign for Abcellera Biologist's.
Simply Wall St · 05/29 11:41
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
AbCellera will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. A live audio webcast of the presentation will be available on AbCellera's Investor Relations website. The company discovers and develops antibody medicines for indications across therapeutic areas.
Barchart · 05/28 15:05
Weekly Report: what happened at ABCL last week (0520-0524)?
Weekly Report · 05/27 09:14
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.